Navigation Links
Fate Therapeutics Announces Promising Data From Phase 1b Study of ProHema at the 2011 American Society of Hematology Annual Conference
Date:12/13/2011

SAN DIEGO, Dec. 13, 2011 /PRNewswire/ -- Fate Therapeutics, Inc. announced today promising clinical results from a Phase 1b trial of ProHema (FT1050-enhanced umbilical cord blood) as part of double-umbilical cord blood (UCB) transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy.  The data are being presented at the 53rd annual American Society of Hematology (ASH) meeting, being held December 10-13, in San Diego, California (Abstract Number: 653; entitled, "FT1050 (16,16-dimethyl Prostaglandin E2)-Enhanced Umbilical Cord Blood Accelerates Hematopoietic Engraftment After Reduced Intensity Conditioning and Double Umbilical Cord Blood Transplantation"). ProHema is a first-in-class therapeutic candidate, consisting of pharmacologically-enhanced hematopoietic stem cells (HSC), designed to improve HSC support during the normal course of a stem cell transplant for the treatment of patients with hematologic malignancies.

The Phase 1b double-UCB study conducted at the Dana-Farber Cancer Institute and the Massachusetts General Hospital achieved its primary objective of demonstrating safety and tolerability of ProHema based upon patient engraftment by Day 42 with greater than 5% chimerism of the ProHema unit. In addition, of the twelve subjects presented in the abstract that received a ProHema unit and an untreated unit, the median time to neutrophil recovery (> 500 cells/uL) was 17.5 days, which compares favorably to a median of 21 days for a historic control group of similarly treated subjects at the Dana-Farber Cancer Institute (n=53).  In addition, the ProHema unit was the dominant source of hematopoiesis in ten of the twelve subjects, suggesting that treatment with ProHema may confer preferential engraftment.

"These clinical trial data support Fate's novel therapeutic approach for the development of stem cell biology-based medici
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. CHEO scientist advances biotherapeutics as published in Cancer Cell
2. Sertoli cells show promise for therapeutics
3. Super-mini vehicles carry therapeutics and imaging agents into body with mega results
4. Reportlinker Adds Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics
5. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
6. UT-Battelle licenses tissue regeneration technologies to NellOne Therapeutics, Inc.
7. IRSF announces translational research award funding to test potential therapeutics for Rett syndrome
8. AACR, NCI and EORTC to host Molecular Targets and Cancer Therapeutics International Conference
9. Fate Therapeutics announces creation of small molecule platform for commercial-scale reprogramming
10. AACR, NCI and EORTC to host molecular targets and cancer therapeutics conference
11. Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... the Straits of Mackinac reverse direction every few days, ... would quickly contaminate shorelines miles away in both lakes ... Michigan study commissioned by the National Wildlife Federation. , ... animations, oil from a hypothetical pipeline break reached Mackinac ... Blanc Island after two days. All three islands are ...
(Date:7/10/2014)... The yellow crazy ant Anoplolepis gracilipes is ranked ... responsible for catastrophic ecological impacts on islands. A new study ... examines and assesses the effects and dangers of the ... of the mature palm forest of the Valle de Mai, ... palm forest of Valle de Mai is a unique ecosystem ...
(Date:7/10/2014)... Columbia University Medical Center (CUMC) researchers have created a ... retinitis pigmentosa (RP), a leading cause of vision loss. ... of induced pluripotent stem (iPS) cell technology to transform ... as a patient-specific model for disease study and preclinical ... H. Tsang, MD, PhD, showed that a form of ...
Breaking Biology News(10 mins):Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 2Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 3Invasion of yellow crazy ant in a Seychelles UNESCO palm forest: Threats and solutions 2Patient-specific stem cells and personalized gene therapy 2Patient-specific stem cells and personalized gene therapy 3
... of proteins and other chemicals that underlies most ... molecules that accelerate chemical reactions between molecules. The ... the synthesis of chemicals and pharmaceuticals, devise new ... therapies. In the August 16 issue of ...
... has journeyed to this section of Antarcticas Amundsen Sea, but ... researchers and a Boerne High School science teacher will join ... sail on a two month expedition. The trip, ... to UTSA, is designed to study the relationship of sea ...
... evidence reported in the August issue of Cell Stem Cell, ... how the HIV/AIDS virus leads to learning and memory deficits, ... the surface of the virus not only kills some mature ... prevents the birth of new brain cells by crippling adult ...
Cached Biology News:MGH researchers describe new way to identify, evolve novel enzymes 2Texas researchers and educators head for Antarctica 2HIV is a 'double hit' to the brain 2
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... 14, 2014 iLab Solutions, the leader in ... new Director of Product Strategy. In this role, Michelle will ... sub-teams to guide in the development of iLab products. Her ... maximum possible benefit to the scientific community by offering the ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... lend materials new characteristics are generally complicated and therefore ... to astonishment when scientists report on new methods which ... they use economically priced starting materials but also do ... framework made of polystyrene This is exactly ...
... BioSpace added Kansas to its annual promotional campaign of biotechnological, ... , , ... , , (Logo:   ... The leading employment Web site for the ...
... , July 29 Omeros Corporation (Nasdaq: ... equity financing facility under which it may sell up to ... to Azimuth Opportunity, Ltd. (the "investor") over a 24-month period. ... free to enter into and consummate other equity, debt and ...
Cached Biology Technology:Empa grows 'sea urchin'-shaped structures 2BioSpace Showcases the Midwest's Growing Life Science Region 2BioSpace Showcases the Midwest's Growing Life Science Region 3Omeros Secures $40 Million Committed Equity Financing Facility 2Omeros Secures $40 Million Committed Equity Financing Facility 3Omeros Secures $40 Million Committed Equity Financing Facility 4
... This 2500ml narrow mouth PYREX low form culture flask ... area to volume ratio. This flask has a heavy ... large marking spot. The neck O.D. is 38mm and ... not use this flask on a heat source smaller ...
... to achieve in many bacterial strains due ... restriction and modification (R-M) systems that cleave ... TypeOne™ Restriction Inhibitor provides a powerful method ... with type I R-M systems. Developed ...
... cassette is designed to allow ... The prokaryotic promoter gb2 driving the ... slightly modified version of the Em7 ... than the generally used Tn5 promoter. ...
Includes a choice of any 3 EasySep mouse selection kits and EasySep magnet...
Biology Products: